Analyzing Biosig Technologies (STEX) and Its Peers

Biosig Technologies (NASDAQ:STEX – Get Free Report) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its competitors? We will compare Biosig Technologies to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares Biosig Technologies and its competitors’ net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Biosig Technologies and its competitors top-line revenue, earnings per share (EPS) and valuation.

Biosig Technologies’ competitors have higher revenue, but lower earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Biosig Technologies has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Biosig Technologies’ competitors have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.

Insider & Institutional Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Biosig Technologies and its competitors, as provided by MarketBeat.

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 38.17%. Given Biosig Technologies’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Biosig Technologies has less favorable growth aspects than its competitors.

Summary

Biosig Technologies competitors beat Biosig Technologies on 8 of the 12 factors compared.

About Biosig Technologies

(Get Free Report)

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.